Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease—How to Choose
Aspirin-exacerbated respiratory disease (AERD) can be a frustratingly complex syndrome to treat. Until recently, standard medical and surgical therapies for patients' asthma and chronic rhinosinusitis with nasal polyposis were the primary treatment modalities available, combined with either com...
Gespeichert in:
| Veröffentlicht in: | The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2022-06, Vol.10 (6), p.1462-1467 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1467 |
|---|---|
| container_issue | 6 |
| container_start_page | 1462 |
| container_title | The journal of allergy and clinical immunology in practice (Cambridge, MA) |
| container_volume | 10 |
| creator | Laidlaw, Tanya M. Chu, Derek K. Stevens, Whitney W. White, Andrew A. |
| description | Aspirin-exacerbated respiratory disease (AERD) can be a frustratingly complex syndrome to treat. Until recently, standard medical and surgical therapies for patients' asthma and chronic rhinosinusitis with nasal polyposis were the primary treatment modalities available, combined with either complete avoidance of all aspirin and nonsteroidal anti-inflammatory medications, or aspirin desensitization and initiation of high-dose aspirin therapy. There are now several targeted respiratory biologics added to the available armament for patients with AERD and choosing between this ever-growing list of options can be daunting for both patients and their clinicians. This review includes our understanding and interpretation of the existing data for each option, along with our own approach to weighing the pros and cons of each treatment for individual patients. |
| doi_str_mv | 10.1016/j.jaip.2021.12.030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2618520771</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213219822000022</els_id><sourcerecordid>2673579204</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-9ca01bfb1c920c68bc0ca3bb1795035e7f1deed50887199ff1f6424a7c3396583</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EolXbF-CALHHhkuCxkzhGXLbbQitVQkJwthxnUhxl48X2FrYnHoIn5Enq1W45cKgv9oy--TXyR8grYCUwaN6N5WjcuuSMQwm8ZII9I8ecgyg4Z_D88Q2qPSJnMY4snxYkq9hLciQqpRSX1TG5X_o5BX-HITqM1M10MU0Ybrfv6SKuXciNC4w4R5fcvUnOz9QHeu785G-djXTI1QEsLn8Zi6EzCXv6BXdNk3zY0gsX0UT8-_vPlf9Jk6fL795HPCUvBjNFPDvcJ-Tbx8uvy6vi5vOn6-XiprCirVKhrGHQDR1YxZlt2s4ya0TXgVQ1EzXKAXrEvmZtK0GpYYChqXhlpBVCNXUrTsjbfe46-B8bjEmvXLQ4TWZGv4maN9DWnEkJGX3zHzr6TZjzdpmSopZ5hSpTfE_Z4GMMOOh1cCsTthqY3snRo97J0Ts5GrjOcvLQ60P0plth_2_kUUUGPuwBzH9x5zDoaB3OFnsX0Cbde_dU_gM5IqHV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2673579204</pqid></control><display><type>article</type><title>Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease—How to Choose</title><source>Alma/SFX Local Collection</source><creator>Laidlaw, Tanya M. ; Chu, Derek K. ; Stevens, Whitney W. ; White, Andrew A.</creator><creatorcontrib>Laidlaw, Tanya M. ; Chu, Derek K. ; Stevens, Whitney W. ; White, Andrew A.</creatorcontrib><description>Aspirin-exacerbated respiratory disease (AERD) can be a frustratingly complex syndrome to treat. Until recently, standard medical and surgical therapies for patients' asthma and chronic rhinosinusitis with nasal polyposis were the primary treatment modalities available, combined with either complete avoidance of all aspirin and nonsteroidal anti-inflammatory medications, or aspirin desensitization and initiation of high-dose aspirin therapy. There are now several targeted respiratory biologics added to the available armament for patients with AERD and choosing between this ever-growing list of options can be daunting for both patients and their clinicians. This review includes our understanding and interpretation of the existing data for each option, along with our own approach to weighing the pros and cons of each treatment for individual patients.</description><identifier>ISSN: 2213-2198</identifier><identifier>EISSN: 2213-2201</identifier><identifier>DOI: 10.1016/j.jaip.2021.12.030</identifier><identifier>PMID: 34999274</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>AERD ; Allergies ; Aspirin ; Aspirin desensitization ; Aspirin-exacerbated respiratory disease ; Asthma ; Benralizumab ; Biological products ; Biologics ; Chronic rhinosinusitis ; Clinical trials ; CRSwNP ; Desensitization (Psychology) ; Drug dosages ; Dupilumab ; Immunosuppressive agents ; Inflammation ; Mepolizumab ; Monoclonal antibodies ; Nasal polyps ; Nonsteroidal anti-inflammatory drugs ; Omalizumab ; Otolaryngology ; Patients ; Polyposis ; Polyps ; Quality of life ; Respiratory diseases ; Rhinitis ; Rhinosinusitis ; Sinuses ; Sinusitis ; Surgery</subject><ispartof>The journal of allergy and clinical immunology in practice (Cambridge, MA), 2022-06, Vol.10 (6), p.1462-1467</ispartof><rights>2022 American Academy of Allergy, Asthma & Immunology</rights><rights>Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.</rights><rights>2022. American Academy of Allergy, Asthma & Immunology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-9ca01bfb1c920c68bc0ca3bb1795035e7f1deed50887199ff1f6424a7c3396583</citedby><cites>FETCH-LOGICAL-c384t-9ca01bfb1c920c68bc0ca3bb1795035e7f1deed50887199ff1f6424a7c3396583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34999274$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laidlaw, Tanya M.</creatorcontrib><creatorcontrib>Chu, Derek K.</creatorcontrib><creatorcontrib>Stevens, Whitney W.</creatorcontrib><creatorcontrib>White, Andrew A.</creatorcontrib><title>Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease—How to Choose</title><title>The journal of allergy and clinical immunology in practice (Cambridge, MA)</title><addtitle>J Allergy Clin Immunol Pract</addtitle><description>Aspirin-exacerbated respiratory disease (AERD) can be a frustratingly complex syndrome to treat. Until recently, standard medical and surgical therapies for patients' asthma and chronic rhinosinusitis with nasal polyposis were the primary treatment modalities available, combined with either complete avoidance of all aspirin and nonsteroidal anti-inflammatory medications, or aspirin desensitization and initiation of high-dose aspirin therapy. There are now several targeted respiratory biologics added to the available armament for patients with AERD and choosing between this ever-growing list of options can be daunting for both patients and their clinicians. This review includes our understanding and interpretation of the existing data for each option, along with our own approach to weighing the pros and cons of each treatment for individual patients.</description><subject>AERD</subject><subject>Allergies</subject><subject>Aspirin</subject><subject>Aspirin desensitization</subject><subject>Aspirin-exacerbated respiratory disease</subject><subject>Asthma</subject><subject>Benralizumab</subject><subject>Biological products</subject><subject>Biologics</subject><subject>Chronic rhinosinusitis</subject><subject>Clinical trials</subject><subject>CRSwNP</subject><subject>Desensitization (Psychology)</subject><subject>Drug dosages</subject><subject>Dupilumab</subject><subject>Immunosuppressive agents</subject><subject>Inflammation</subject><subject>Mepolizumab</subject><subject>Monoclonal antibodies</subject><subject>Nasal polyps</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Omalizumab</subject><subject>Otolaryngology</subject><subject>Patients</subject><subject>Polyposis</subject><subject>Polyps</subject><subject>Quality of life</subject><subject>Respiratory diseases</subject><subject>Rhinitis</subject><subject>Rhinosinusitis</subject><subject>Sinuses</subject><subject>Sinusitis</subject><subject>Surgery</subject><issn>2213-2198</issn><issn>2213-2201</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAQhi0EolXbF-CALHHhkuCxkzhGXLbbQitVQkJwthxnUhxl48X2FrYnHoIn5Enq1W45cKgv9oy--TXyR8grYCUwaN6N5WjcuuSMQwm8ZII9I8ecgyg4Z_D88Q2qPSJnMY4snxYkq9hLciQqpRSX1TG5X_o5BX-HITqM1M10MU0Ybrfv6SKuXciNC4w4R5fcvUnOz9QHeu785G-djXTI1QEsLn8Zi6EzCXv6BXdNk3zY0gsX0UT8-_vPlf9Jk6fL795HPCUvBjNFPDvcJ-Tbx8uvy6vi5vOn6-XiprCirVKhrGHQDR1YxZlt2s4ya0TXgVQ1EzXKAXrEvmZtK0GpYYChqXhlpBVCNXUrTsjbfe46-B8bjEmvXLQ4TWZGv4maN9DWnEkJGX3zHzr6TZjzdpmSopZ5hSpTfE_Z4GMMOOh1cCsTthqY3snRo97J0Ts5GrjOcvLQ60P0plth_2_kUUUGPuwBzH9x5zDoaB3OFnsX0Cbde_dU_gM5IqHV</recordid><startdate>202206</startdate><enddate>202206</enddate><creator>Laidlaw, Tanya M.</creator><creator>Chu, Derek K.</creator><creator>Stevens, Whitney W.</creator><creator>White, Andrew A.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>202206</creationdate><title>Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease—How to Choose</title><author>Laidlaw, Tanya M. ; Chu, Derek K. ; Stevens, Whitney W. ; White, Andrew A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-9ca01bfb1c920c68bc0ca3bb1795035e7f1deed50887199ff1f6424a7c3396583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>AERD</topic><topic>Allergies</topic><topic>Aspirin</topic><topic>Aspirin desensitization</topic><topic>Aspirin-exacerbated respiratory disease</topic><topic>Asthma</topic><topic>Benralizumab</topic><topic>Biological products</topic><topic>Biologics</topic><topic>Chronic rhinosinusitis</topic><topic>Clinical trials</topic><topic>CRSwNP</topic><topic>Desensitization (Psychology)</topic><topic>Drug dosages</topic><topic>Dupilumab</topic><topic>Immunosuppressive agents</topic><topic>Inflammation</topic><topic>Mepolizumab</topic><topic>Monoclonal antibodies</topic><topic>Nasal polyps</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Omalizumab</topic><topic>Otolaryngology</topic><topic>Patients</topic><topic>Polyposis</topic><topic>Polyps</topic><topic>Quality of life</topic><topic>Respiratory diseases</topic><topic>Rhinitis</topic><topic>Rhinosinusitis</topic><topic>Sinuses</topic><topic>Sinusitis</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laidlaw, Tanya M.</creatorcontrib><creatorcontrib>Chu, Derek K.</creatorcontrib><creatorcontrib>Stevens, Whitney W.</creatorcontrib><creatorcontrib>White, Andrew A.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laidlaw, Tanya M.</au><au>Chu, Derek K.</au><au>Stevens, Whitney W.</au><au>White, Andrew A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease—How to Choose</atitle><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle><addtitle>J Allergy Clin Immunol Pract</addtitle><date>2022-06</date><risdate>2022</risdate><volume>10</volume><issue>6</issue><spage>1462</spage><epage>1467</epage><pages>1462-1467</pages><issn>2213-2198</issn><eissn>2213-2201</eissn><abstract>Aspirin-exacerbated respiratory disease (AERD) can be a frustratingly complex syndrome to treat. Until recently, standard medical and surgical therapies for patients' asthma and chronic rhinosinusitis with nasal polyposis were the primary treatment modalities available, combined with either complete avoidance of all aspirin and nonsteroidal anti-inflammatory medications, or aspirin desensitization and initiation of high-dose aspirin therapy. There are now several targeted respiratory biologics added to the available armament for patients with AERD and choosing between this ever-growing list of options can be daunting for both patients and their clinicians. This review includes our understanding and interpretation of the existing data for each option, along with our own approach to weighing the pros and cons of each treatment for individual patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34999274</pmid><doi>10.1016/j.jaip.2021.12.030</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2213-2198 |
| ispartof | The journal of allergy and clinical immunology in practice (Cambridge, MA), 2022-06, Vol.10 (6), p.1462-1467 |
| issn | 2213-2198 2213-2201 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2618520771 |
| source | Alma/SFX Local Collection |
| subjects | AERD Allergies Aspirin Aspirin desensitization Aspirin-exacerbated respiratory disease Asthma Benralizumab Biological products Biologics Chronic rhinosinusitis Clinical trials CRSwNP Desensitization (Psychology) Drug dosages Dupilumab Immunosuppressive agents Inflammation Mepolizumab Monoclonal antibodies Nasal polyps Nonsteroidal anti-inflammatory drugs Omalizumab Otolaryngology Patients Polyposis Polyps Quality of life Respiratory diseases Rhinitis Rhinosinusitis Sinuses Sinusitis Surgery |
| title | Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease—How to Choose |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T16%3A10%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Controversies%20in%20Allergy:%20Aspirin%20Desensitization%20or%20Biologics%20for%20Aspirin-Exacerbated%20Respiratory%20Disease%E2%80%94How%20to%20Choose&rft.jtitle=The%20journal%20of%20allergy%20and%20clinical%20immunology%20in%20practice%20(Cambridge,%20MA)&rft.au=Laidlaw,%20Tanya%20M.&rft.date=2022-06&rft.volume=10&rft.issue=6&rft.spage=1462&rft.epage=1467&rft.pages=1462-1467&rft.issn=2213-2198&rft.eissn=2213-2201&rft_id=info:doi/10.1016/j.jaip.2021.12.030&rft_dat=%3Cproquest_cross%3E2673579204%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2673579204&rft_id=info:pmid/34999274&rft_els_id=S2213219822000022&rfr_iscdi=true |